Sandeep Kulkarni shares a framework from his chairman, Clay Siegall: a biotech can fail, get acquired after short-term success, get acquired after long-term success, or achieve rare 'escape velocity' to stay independent. This pragmatic view frames acquisition not as a lesser option but as a primary successful outcome for most.

Instead of a one-size-fits-all approach, biotech leaders should first identify their next logical investor. Then, they should tailor their clinical strategy and milestones to directly address the uncertainties that specific investor class needs resolved.

While the CEO of Transgene aspires to launch their product independently in Europe, he acknowledges the immense cost of a Phase 3 trial. A partnership with a large pharmaceutical company is viewed as the most realistic "best case scenario" to accelerate development and de-risk the final, most expensive stage.

CEO Michael Metzger views the high-risk, capital-intensive clinical development phase as a "project" focused on investment and milestones. The organization only transitions into a "business" at the key turning point of drug approval and commercial launch. This mental model helps manage resources and expectations through the long, uncertain pre-commercial journey.

Inozyme planned to self-commercialize but sold to BioMarin after realizing a larger company with existing infrastructure could get its drug to patients more effectively. This prioritizes the mission over ego, a critical consideration for any startup leadership team.

Ainsworth believes a responsible biotech entrepreneur envisions the end goal—acquisition or IPO—from day one. At RetroSense, this meant constantly engaging with potential acquirers like Allergan to understand their needs and generate the specific data required to become an attractive M&A target.

CEO Brett Monia pivoted Ionis from a pure R&D partnership model to a fully integrated biotech. He argued that relying on partners stalled promising drugs and suppressed the company's valuation, necessitating the development of in-house commercial capabilities.

For a biotech with an established commercial infrastructure, the most efficient growth strategy is to in-license late-stage or already-approved products. This leverages the existing sales force and operational teams to sell new products without adding significant overhead, maximizing operational efficiency and revenue.

The ideal CEO for a biotech startup changes as it matures. The person excelling at early-stage discovery may not be the best for taking a company public. Founders should see their role as a finite 'tour of duty,' focusing on the company's immediate needs rather than assuming permanent leadership.